Učitavanje...
ASCO 2018: highlights in HER2-positive metastatic breast cancer
At the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-positive metastatic breast cancer were presented. While not immediately practice changing, these trials indicate the future directions of drug development in this field. Early phase studies with novel antibody-drug conjug...
Spremljeno u:
| Izdano u: | Memo |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Vienna
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280772/ https://ncbi.nlm.nih.gov/pubmed/30595754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-018-0441-x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|